Recombinant angiotensin II therapy in a child with cardiac dysfunction and Pandoraea and Candida sepsis

Area of Science:

• Cardiology
• Pediatrics
• Pharmacology

Background:

• Refractory hypotension is a critical condition often associated with septic shock.
• Disruptions in the renin-angiotensin-aldosterone system (RAAS), indicated by elevated direct renin levels, can complicate hypotension management.
• Recombinant angiotensin II is an emerging therapeutic option for such complex cases.

Purpose of the Study:

• To evaluate the efficacy of recombinant angiotensin II in a pediatric patient with refractory hypotension.
• To assess the response to recombinant angiotensin II in the context of septic shock and right ventricular hypertension.

Main Methods:

• Case report of a pediatric patient.
• Administration of recombinant angiotensin II for refractory hypotension.
• Monitoring of hemodynamic parameters and clinical response.

Main Results:

• The pediatric patient experienced a positive response to recombinant angiotensin II.
• Recombinant angiotensin II effectively managed refractory hypotension in the setting of septic shock and right ventricular hypertension.
• The treatment was relevant for a patient with a disrupted renin-angiotensin-aldosterone system.

Conclusions:

• Recombinant angiotensin II shows promise as a treatment for refractory hypotension in pediatric patients with complex conditions.
• This case highlights the potential utility of recombinant angiotensin II in managing severe hypotension associated with septic shock and right ventricular hypertension.
• Further research is warranted to establish the role of recombinant angiotensin II in pediatric critical care.